Morepen Laboratories Reports Over 390% Rise in Q1 Net Profit with Revenue Growth
Morepen Laboratories reported a significant rise in its consolidated net profit for Q1 FY27, increasing by approximately 394-425% year-on-year to around Rs 56.35 crore. Revenue from operations grew by 34% to about Rs 570 crore, marking the highest quarterly revenue for the company. EBITDA surged over 200%, with margins improving due to better operating leverage and product mix. Growth was driven by strong performance in API, CDMO, and medical devices segments, alongside increased exports. The board approved the re-appointment of Chairman Sushil Suri and proposed a medical devices business hiving-off.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (71/100). Lens Score 36/100.
Outlets measured: thetribune, businessstandard, businessstandard, businessstandard, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment ranged widely across outlets — from 55/100 to 85/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
freepressjournal broke this story on 4 Aug, 08:52 am. Other outlets followed.